796967-18-5

Usage

Uses

Used in Organic Synthesis:
Urea, N-(2-fluoro-5-Methylphenyl)-N'-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolanyl)phenyl]is utilized as a key intermediate in organic synthesis for the creation of complex organic molecules. Its unique structure allows for specific reactions that can lead to the formation of desired products in the synthesis of pharmaceuticals, agrochemicals, or other specialty chemicals.
Used as a Reagent in Chemical Reactions:
In the realm of chemical research and development, Urea, N-(2-fluoro-5-Methylphenyl)-N'-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolanyl)phenyl]serves as a reagent that can facilitate or enhance certain chemical reactions. Its role may be crucial in processes such as cross-coupling, where it could help in the formation of carbon-carbon or carbon-heteroatom bonds, essential for the synthesis of advanced materials or complex organic compounds.
Used in Research and Development:
Urea, N-(2-fluoro-5-Methylphenyl)-N'-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborola n-2-yl)phenyl]is also valuable in the research and development sector, where it can be employed to study the effects of structural modifications on chemical and physical properties. Understanding how changes in the molecular structure influence reactivity and stability can provide insights into the design of new materials and catalysts.
Used in Pharmaceutical Development:
Given its complex structure, Urea, N-(2-fluoro-5-Methylphenyl)-N'-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolanyl)phenyl]may have potential applications in the pharmaceutical industry. It could be used as a building block for the development of new drugs, where its unique properties might contribute to novel mechanisms of action or improved drug delivery systems.
Used in Material Science:
In the field of material science, Urea, N-(2-fluoro-5-Methylphenyl)-N'-[4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborola n-2-yl)phenyl]- could be explored for its potential to contribute to the development of new materials with specific properties, such as high thermal stability, unique electronic characteristics, or specific catalytic activities.

Upstream product

• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 452-84-6 3-amino-4-fluorotoluene 
• 106-40-1 4-bromo-aniline 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 796967-16-3 linifanib 
• 819058-30-5 C₂₁H₁₇FN₄OS 

Relevant academic research and scientific papers

UREA INHIBITORS OF MICRO-RNA

The present disclosure relates to compounds and methods which may be useful as inhibitors of the expression of miRNA, for use in the treatment or prevention of cancer.

N - (4 - (3 - amino - 1 H - indazole - 4 - yl) phenyl) - N' - (2 - fluoro - 5 - methylphenyl) urea intermediate preparation method

The invention provides a preparation method of N-(4-(3-amino-1H-indazol-4-yl) phenyl)-N'-(2-fluoro-5-methylphenyl) urea and an intermediate thereof. Specifically, the invention provides a preparation method of a borate ester compound as shown in a formula I, and the preparation method comprises the following steps: enabling a compound as shown in a formula III to react with a compound as shown in a formula IV to generate a compound as shown in a formula V, and enabling the compound as shown in the formula V to react with a boron reagent to generate the compound as shown in the formula I. The method has the characteristics of convenience in reaction, easiness in obtainment of the intermediate, high yield, high product purity of above 98.5%, low cost of raw materials and the like, and is suitable for industrial application.

Novel Hydroximic Acid Derivative and Medical Application Thereof

The present invention relates to a kind of new hydroximic acid derivatives, in particular, hydroximic acid derivatives of pyrazolopyrimidine and their medical applications, which have inhibition to histone deacetylase 1 and two kinds of tyrosine kinases (vascular endothelial cell growth factor receptors as well as platelet-derived growth factor receptors) simultaneously, and thus can be used for treatment of diseases related to those three kinds of enzymes. This kind of compounds both exerts a synergistic effect sufficiently to increase biological activity, and avoids problems caused by different properties and metabolisms, therefore is more practical and has good prospects.

Linifanib-a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator

In this study we demonstrate that linifanib, a multi-targeted receptor tyrosine kinase inhibitor, with a key urea containing pharmacophore, self-assembles into a hydrogel in the presence of low amounts of solvent. We demonstrate the role of the urea functional group and that of fluorine substitution on the adjacent aromatic ring in promoting self-assembly. We have also shown that linifanib has superior mechanical strength to two structurally related analogues and hence increased potential for localisation at an injection site for drug delivery applications. This journal is

UREA DERIVATIVES AND USES THEREOF

The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

The discovery and development of a safe, practical synthesis of ABT-869

The discovery, development and implementation of two chemical routes to ABT-869 is reported. Optimization of the first-generation heterocycle formation and Suzuki coupling is briefly described. Key features of the second-generation synthesis include the development of a safe hydrazine condensation by utilizing an inorganic base to increase the onset temperature of exothermic decomposition. The second-generation Suzuki reaction is discussed in detail, culminating in the use of an oxygen monitor as a PAT to maximize reproducibility on scale.

3-Amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases

A series of benzoisoxazoles and benzoisothiazoles have been synthesized and evaluated as inhibitors of receptor tyrosine kinases (RTKs). Structure-activity relationship studies led to the identification of 3-amino benzo[d]isoxazoles, incorporating a N,N′-

SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE

The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.

SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5- methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor

In our continued efforts to search for potent and novel receptor tyrosine kinase (RTK) inhibitors as potential anticancer agents, we discovered, through a structure-based design, that 3-aminoindazole could serve as an efficient hinge-binding template for kinase inhibitors. By incorporating an N,N′-diaryl urea moiety at the C4-position of 3-aminodazole, a series of RTK inhibitors were generated, which potently inhibited the tyrosine kinase activity of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor families. A number of compounds with potent oral activity were identified by utilizing an estradiol-induced mouse uterine edema model and an HT1080 human fibrosarcoma xenograft tumor model. In particular, compound 17p (ABT-869) was found to possess favorable pharmacokinetic profiles across different species and display significant tumor growth inhibition in multiple preclinical animal models.